Magnetic Resonance Spectroscopy Study of Oxygen Therapy in Ischemic Stroke

Aneesh B. Singhal, MD; Eva Ratai, PhD; Thomas Benner, PhD; Mark Vangel, PhD; Vallent Lee, BA; Walter J. Koroshetz, MD; Pamela W. Schaefer, MD; A. Gregory Sorensen, MD; R. Gilberto Gonzalez, MD, PhD

Background and Purpose—Recent studies suggest that normobaric oxygen therapy (NBO) is neuroprotective in acute ischemic stroke.1 In contrast to hyperbaric oxygenation, which has multiple molecular/biochemical effects, NBO’s mechanisms are relatively unknown. We investigated NBO’s metabolic effects on acutely ischemic brain tissues using multivoxel magnetic resonance spectroscopic imaging (MRSI) and diffusion-perfusion MRI (DWI and PWI).

Methods

MRSI was performed in seven patients; one data set was discarded due to poor coregistration and motion artifact. Analyzable data were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot study of NBO in stroke.1 Detailed patient selection criteria are published1; eligible patients were obtained in 6 patients, including 5 consecutively enrolled in a pilot stud...
Results

We studied 4 NBO-treated patients (mean age 70±23 years) and 2 who received room air (control subjects, mean age 65±23 years). The median time interval from baseline to subsequent scans was similar (NBO, 4.6 hours and 24.7 hours; control subjects, 4.5 hours and 24.1 hours). At baseline, there was no significant difference in mean DWI lesion volumes (NBO, 42.5 mL, control subjects, 56.3 mL; \( P=0.75 \)) or mean PWI lesion volumes (NBO, 200 mL, control subjects, 213 mL; \( P=0.9 \)). Median National Institutes of Health Scale scores changed from baseline to 4 hours to 24 hours as follows: NBO group, 16 to 12 to 13.5; control subjects, 17.5 to 19.5 to 19.5. Reperfusion (>50% reduction in PWI lesion volume\(^1\)) occurred by 4 hours in one control subject and by 24 hours in 2 NBO patients.

At baseline, voxel-by-voxel analysis showed significant correlation between ADC and NAA/Sum (\( R=0.68, P<0.001 \)) and Lac/Sum (\( R=-0.69, P<0.001 \)). These correlations remained significant (\( P<0.001 \)) at 4 hours (ADC versus NAA/Sum, \( R=0.42 \); versus Lac/Sum, \( R=-0.46 \)) and at 24 hours (ADC versus NAA/Sum, \( R=0.54 \); versus Lac/Sum, \( R=-0.66 \)). In addition, we calculated the average of all within-subject voxels and correlated mean values. Despite small patient numbers, there was excellent correlation (Figure 2) between mean ADC and MRSI markers at baseline (ADC versus NAA/Sum, \( R=0.90, P=0.015 \); ADC versus Lac/Sum, \( R=-0.88, P=0.021 \)). These correlations persisted at 4 hours (ADC versus NAA/Sum, \( R=0.85, P=0.033 \); ADC versus Lac/Sum, \( R=-0.84, P=0.037 \)) and tended to correlate at 24 hours (ADC versus NAA/Sum, \( R=0.77, P=0.07 \); ADC versus Lac/Sum, \( R=-0.81, P=0.048 \)).

On qualitative MRSI maps, lactate was observed predominantly within DWI-bright regions, although some lactate was also observed in mismatch regions. Changes in lactate paral-
led the changes in DWI lesion size. Temporal changes in mean Lac/Sum values and mean NAA/Sum values in both groups are depicted in Figure 3. Although these changes proved significant (analysis of variance) when individual voxels were treated as independent, these changes were not statistically significant when within-subject voxels were averaged, likely because of the small patient numbers. Nevertheless, subject-level changes and changes within different brain regions were meaningful. Both control subjects showed progressive increases in Lac/Sum and decreases in NAA/Sum; the changes were greater in DWI-bright as compared with mismatch regions. In all NBO-patients, mean Lac/Sum decreased during therapy and further decreased posttherapy in the 2 patients with reperfusion, suggesting that NBO’s beneficial effects may not be sustainable with persistent hypoperfusion. NAA/Sum did not decline in NBO-treated patients (change from pre- to post-therapy was +1% in the NBO group; −25% in control subjects).

The change in mean Lac/Sum from baseline to 4 hours (during therapy) tended to be different ($P=0.09$) between NBO and control groups and occurred mainly in DWI-bright regions ($P=0.058$) rather than mismatch regions ($P=0.43$). The change in mean NAA/Sum from baseline to 4 hours was significantly different ($P=0.049$) between NBO and control groups and occurred mainly in DWI-bright regions ($P=0.046$) rather than mismatch regions ($P=0.47$).
Discussion

Monitoring signal levels of Lac and NAA by MRSI provides important information about the state of acutely ischemic brain tissues\(^3\) and may be useful in assessing prognosis.\(^4\) This first study of serial multivoxel MRSI with DWI/PWI in hyperacute ischemic stroke provides important insights into the temporal evolution and correlation of ADC and MRSI markers. MRSI marker levels correlated strongly with ADC values at multiple time points after stroke, extending previous observations\(^5\) and demonstrating that DWI abnormalities reflect disturbed cerebral metabolism.

Our primary objective was to investigate NBO’s metabolic effects. We found that NBO reduced brain lactate and preserved NAA (a marker of neuronal integrity and mitochondrial function), suggesting that NBO improves aerobic metabolism and restores mitochondrial function either from direct effects on tissue oxygenation or indirectly from alterations in cerebral hemodynamics.\(^1\) The control group data are consistent with previous studies showing increased lactate with reduced NAA in T2-hyperintense infarcted regions and increased lactate with normal NAA in perifarct regions.\(^6\) Furthermore, the observed abnormalities in lactate and NAA in mismatch regions are consistent with published data showing increased lactate and reduced NAA outside ADC or DWI lesion boundaries,\(^3,7\) including in the early stages after stroke.\(^8\)

The small number of patients is a limitation of our study. A major strength, however, is that each patient was carefully studied with 3 parameters of stroke-related injury (MRSI markers, DWI abnormalities, National Institutes of Health Stroke Scale scores), each measured before, during, and after therapy. All 3 parameters improved during NBO and worsened after NBO. These preliminary results strengthen our contention that NBO, by resuscitating acutely ischemic tissues, may be useful in extending the narrow time window for stroke thrombolysis.\(^1\)

Acknowledgments

We thank Vallent Lee for his help with data analysis. We are grateful to Eng Lo, PhD, F. S. Buonanno, MD, and our residents, fellows, nurses, and MRI technicians for their assistance with this study.

Sources of Funding

Supported in part by NIH grants R01 NS38477 (A.G.S.), R01 NS051412 (A.B.S.), P50 NS051343 (W.J.K.), and R01 NS050041 (R.G.G.).

Disclosures

None.

References

Magnetic Resonance Spectroscopy Study of Oxygen Therapy in Ischemic Stroke

*Stroke.* 2007;38:2851-2854; originally published online August 30, 2007;
doi: 10.1161/STROKEAHA.107.487280

*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/38/10/2851

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Stroke* is online at:
http://stroke.ahajournals.org/subscriptions/